Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16085903 | 0.84 | RNASE1 (0.37) | — | |
| SCHEMBL14714996 | 0.83 | TK1 (0.46) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL14946754 | 0.83 | TK1 (0.46) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL2497338 | 0.82 | LMNA (0.36) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL16085973 | 0.82 | LMNA (0.39) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL3205916 | 0.81 | TYMS (0.43) | — | |
| SCHEMBL20953781 | 0.81 | TK1 (0.51) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL13488841 | 0.81 | TK1 (0.51) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL2494647 | 0.81 | TK1 (0.51) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL14946758 | 0.81 | TK1 (0.51) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781599-B1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-9873879-B2 | Nucleic acid fragment binding to target protein | TAGCYX BIOTECHNOLOGIES (JP) | 2018-01-23 | — | — | US | disclosed |
| US-20170073683-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2017-03-16 | — | — | US | disclosed |
| US-9540650-B2 | Nucleic acid fragment binding to target protein | TAGCYX BIOTECHNOLOGIES (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9285319-B2 | Nucleic acid base analogs with quenching and fluorescent activities and applications thereof | RIKEN (JP) | 2016-03-15 | — | — | US | disclosed |
| US-20150119254-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2015-04-30 | — | — | US | disclosed |
| EP-2781599-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | Riken (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20130122506-A1 | NUCLEIC ACID BASE ANALOGS WITH QUENCHING AND FLUORESCENT ACTIVITIES AND APPLICATIONS THEREOF | TAGCYX BIOTECHNOLOGIES C/O RIKEN (JP) | 2013-05-16 | — | — | US | disclosed |
| EP-2562255-A1 | NUCLEIC ACID BASE ANALOG WITH QUENCHING CHARACTERISTICS AND FLUORESCENCE AND APPLICATION THEREOF | Riken (JP) | 2013-02-27 | — | — | EP | disclosed |
| EP-1970445-B1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | RIKEN (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-8030478-B2 | Method for nucleic acid replication and novel artificial base pairs | RIKEN (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | RIKEN (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119254-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TARBP1, DNTT, FABP1 | TK1 715/4885LMNA 1973/4885SMN1; SMN2 3806/4885 |
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | POLM, POLL, POLRMT | TK1 78/4885LMNA 3624/4885SMN1; SMN2 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.